GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Procaps Group
How did Procaps Group rework its sales and marketing to go global?
Procaps Group shifted from regional contract manufacturing to a global specialty-pharma partner after its 2021 Nasdaq listing, accelerating North American entry in 2024–2025 via proprietary Unigel and Versagel platforms and targeting higher-margin channels.
Sales focus blends direct business development with OEM partnerships, specialty distributors, and targeted digital campaigns; marketing uses data-driven brand equity tactics and clinical-led content to support B2B and B2C uptake.
Key product and channel tactics emphasize specialty formulations, clinical evidence, regulated-market compliance, and strategic licensing; see Procaps Group Porter's Five Forces Analysis.
How Does Procaps Group Reach Its Customers?
Procaps Group's sales channels combine a direct field force, regional business units, a global CDMO division, and digital platforms to deliver Rx, OTC and nutraceuticals across 13 Latin American countries and into North America by 2025.
Direct Sales Force
A commercial team of over 1,500 representatives targets healthcare professionals, hospital networks and pharmacy chains, forming the backbone of the Procaps Group sales strategy in Latin America.
Regional Business Units
Operations are organized into Next (proprietary brands), Procaps Colombia, CAN (Central America and the Andean Region) and CAS (Southern Cone) to tailor Procaps Group marketing strategy and distribution by market.
CDMO — Softigel
Softigel operates as a high-growth B2B channel providing contract development and manufacturing to global pharma clients; a strategic shift toward the U.S. is anchored by the West Palm Beach facility.
Digital and E‑commerce
Integrated e-commerce and digital pharmacy portals support direct-to-consumer nutraceutical sales, creating an omnichannel Procaps Group sales approach that complements physical distribution.
By 2025, international markets outside Colombia represent approximately 55% of revenue, driven by direct institutional sales, Softigel B2B contracts and strategic wholesale partnerships targeting regulated North American and LATAM channels.
Channel Effectiveness & Strategic Priorities
Sales performance prioritizes prescription penetration in hospitals, retail pharmacy coverage and CDMO revenue growth; digital channels support consumer acquisition and product launches.
- Direct institutional model remains the primary Rx/OTC driver across 13 countries
- Softigel focuses on U.S. market expansion via the West Palm Beach hub
- Hybrid omnichannel strategy increases access to nutraceutical consumers online and in-store
- Regional units (Next, Procaps Colombia, CAN, CAS) enable market-specific go-to-market execution
Relevant resources on organization and values are available in the company overview: Mission, Vision & Core Values of Procaps Group
What Marketing Tactics Does Procaps Group Use?
Procaps Group's marketing tactics blend scientific B2B credibility with consumer-focused campaigns, prioritizing digital channels, data-driven personalization and targeted traditional media in Latin America to drive both prescription adoption and OTC growth.
Dual-track positioning
B2B efforts emphasize clinical evidence for i-Caps and Unigel; OTC brands use lifestyle messaging to build consumer preference.
Digital-first investments
Advanced SEO and content marketing in 2025 target product technologies as category standards and improve organic visibility.
Data-driven CRM
Salesforce segmentation of HCPs by prescription patterns enables highly personalized outreach and promotion.
Social media mix
LinkedIn drives B2B lead generation and clinical thought leadership; Instagram supports lifestyle nutraceuticals and brand affinity.
Traditional media in LATAM
TV and radio remain active for Gelicart and Colnatur while medical education and congress sponsorships reinforce prescriber relationships.
Influencer & clinical partnerships
From 2025, certified dermatologists and nutritionists amplify clinical claims and consumer trust through vetted influencer collaborations.
Analytics-driven optimization
Predictive analytics reallocates marketing spend toward high-growth areas such as cardiology and women’s health, improving ROI and market share expansion.
- CRM-enabled segmentation increases targeted HCP conversion rates; procurement in 2024–2025 showed uplift in sample-to-prescription conversion for prioritized cohorts.
- SEO and content programs boosted organic traffic to product technology pages, supporting i-Caps and Unigel thought leadership and reducing paid CAC.
- Influencer campaigns in 2025 delivered measurable engagement lifts for nutraceutical SKUs, with third-party validation improving purchase intent.
- Traditional media investments in LATAM sustain mass-reach while digital channels drive measurable lead-gen and e-commerce conversion.
Relevant strategic detail and further context on Procaps Group sales strategy and go-to-market dynamics are covered in Revenue Streams & Business Model of Procaps Group.
How Is Procaps Group Positioned in the Market?
Procaps Group positions itself as a Global Specialty Pharma focused on 'Healthier lives through innovative oral delivery systems', targeting B2B partners needing complex manufacturing and patients seeking fast-acting, easy-to-swallow medicines.
Core Positioning
The brand emphasizes technical superiority and agility versus traditional manufacturers, leveraging proprietary i-Caps technology to encapsulate unstable formulations.
Visual Identity
Visuals are clean, clinical and modern to reinforce trust among pharmaceutical customers and consumers seeking premium oral delivery solutions.
Quality and Certifications
Procaps holds approvals from FDA, MHRA and TGA, supporting a 'quality-first' reputation—critical in Latin America where it is viewed as a premium alternative to generics.
Sustainability & Trust
A commitment to sustainability and a visible Procaps 'Seal of Quality' on products combats counterfeit risks and builds customer confidence.
The brand strategy aligns product, regulatory and commercial messaging to support Procaps Group sales strategy, Procaps Group marketing strategy and Procaps Group business strategy across markets.
i-Caps Technology
i-Caps enables stabilization of complex actives, differentiating Procaps in pharmaceutical marketing Procaps Group and supporting higher-margin contracts with global partners.
Nutraceutical Positioning
Its nutraceutical line is presented as science-backed preventative health, bridging traditional medicine and wellness trends to capture growing consumer demand.
Target Audiences
Two-pronged targeting: B2B pharma customers for complex manufacturing solutions and end consumers prioritizing convenience and efficacy.
Centralized Brand Governance
A centralized marketing hub enforces brand consistency and the Procaps 'Seal of Quality' across packaging, digital channels and B2B materials.
Commercial Impact
Quality certifications and proprietary tech support premium pricing: Procaps reports higher ASPs in Latin America versus regional generic peers, aiding margin resilience.
Sales & Marketing Alignment
Positioning underpins Procaps Group sales approach and Procaps Group competitive strategy, enabling targeted go-to-market plays for new products and regulated market entry.
Key Assets & Metrics
Brand assets and measured outcomes that validate positioning:
- Proprietary i-Caps technology drives differentiated formulation success rates versus industry baselines.
- Certifications (FDA, MHRA, TGA) support B2B contract wins in regulated markets.
- Visible Procaps 'Seal of Quality' reduces perceived counterfeit risk and improves customer retention.
- Nutraceutical sales growth aligns with category expansion into preventative health segments.
For context on market competitors and strategic positioning, see Competitors Landscape of Procaps Group, which complements analysis of Procaps Group digital marketing initiatives in pharma and its go-to-market strategy for new products.
What Are Procaps Group’s Most Notable Campaigns?
Key Campaigns in 2024–2025 centered on targeted B2B innovation and region-specific consumer activations that drove contract wins and retail growth across North America, Europe and Latin America.
Unigel: The Power of One
The 2025 global B2B campaign showcased capsule-in-capsule technology to R&D heads via immersive VR demos and white papers, yielding a 20 percent increase in new CDMO contracts within nine months and boosting Procaps Group sales strategy visibility in North America and Europe.
Gelicart: Move with Purpose
The Latin America consumer push paired athletes and orthopedic specialists to promote bioactive collagen peptides; TV, POS in over 5,000 pharmacies and heavy social media led to a 15 percent year-over-year sales lift for the Gelicart line.
Green Caps (Versagel)
The 2024–2025 sustainability initiative launched plant-based softgel shells, capturing vegan and eco-conscious segments and earning industry awards for sustainable packaging and formulation, supporting the Procaps Group marketing strategy emphasis on ESG-driven product innovation.
Integrated Measurement
Campaign measurement combined CRM-sourced lead conversion, CDMO contract signings and POS sell-through; marketing ROI analyses reported a double-digit uplift in high-value B2B contracts and retail turnover during campaign windows.
These campaigns illustrate Procaps Group business strategy trade-offs between specialized B2B technical positioning and broad consumer-facing brand health tactics, aligning with the company’s omnichannel and partnership-driven go-to-market approach; see further context in Growth Strategy of Procaps Group
Target audiences
B2B: R&D heads, C-suite biotech partners. Consumer: athletes, orthopedists and health-conscious shoppers across LATAM.
Channels used
VR demos, white papers, TV, POS displays in >5,000 pharmacies, social media and clinical endorsements to support Pharmaceutical marketing Procaps Group initiatives.
Key outcomes
New CDMO contracts up 20 percent; Gelicart sales up 15 percent YoY; sustainable product wins improved market penetration.
Competitive positioning
Campaigns reinforced Procaps Group competitive strategy by emphasizing unique formulation capabilities and ESG-aligned softgel differentiation.
Sales enablement
VR assets and white papers were integrated into sales training, improving conversion rates among technical buyers and supporting the Procaps Group sales approach.
Market focus
Priority markets: North America, Europe for B2B; Latin America for consumer health, reflecting a targeted international sales framework.
- What is Brief History of Procaps Group Company?
- What is Competitive Landscape of Procaps Group Company?
- What is Growth Strategy and Future Prospects of Procaps Group Company?
- How Does Procaps Group Company Work?
- What are Mission Vision & Core Values of Procaps Group Company?
- Who Owns Procaps Group Company?
- What is Customer Demographics and Target Market of Procaps Group Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.